litlas
ログインアカウント作成

Howard L. McLeod

1992–2025 年に発表

別表記
Howard L McLeod
165
論文数
31,281
被引用数
101
h 指数
164
i10 指数

被引用数

Howard L. McLeod の年別被引用数1993 年: 被引用 4 件1994 年: 被引用 1 件1995 年: 被引用 9 件1996 年: 被引用 6 件1997 年: 被引用 12 件1998 年: 被引用 27 件1999 年: 被引用 29 件2000 年: 被引用 52 件2001 年: 被引用 63 件2002 年: 被引用 103 件2003 年: 被引用 144 件2004 年: 被引用 218 件2005 年: 被引用 276 件2006 年: 被引用 299 件2007 年: 被引用 261 件2008 年: 被引用 283 件2009 年: 被引用 283 件2010 年: 被引用 292 件2011 年: 被引用 249 件2012 年: 被引用 212 件2013 年: 被引用 240 件2014 年: 被引用 230 件2015 年: 被引用 260 件2016 年: 被引用 203 件2017 年: 被引用 224 件2018 年: 被引用 191 件2019 年: 被引用 742 件2020 年: 被引用 740 件2021 年: 被引用 763 件2022 年: 被引用 522 件2023 年: 被引用 366 件2024 年: 被引用 592 件2025 年: 被引用 265 件2026 年: 被引用 6 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,746 件、この内訳の 27.1%中国: 引用元論文 838 件、この内訳の 8.3%イギリス: 引用元論文 704 件、この内訳の 6.9%ドイツ: 引用元論文 433 件、この内訳の 4.3%イタリア: 引用元論文 410 件、この内訳の 4%カナダ: 引用元論文 388 件、この内訳の 3.8%オランダ: 引用元論文 365 件、この内訳の 3.6%日本: 引用元論文 333 件、この内訳の 3.3%フランス: 引用元論文 303 件、この内訳の 3%スペイン: 引用元論文 260 件、この内訳の 2.6%オーストラリア: 引用元論文 250 件、この内訳の 2.5%インド: 引用元論文 233 件、この内訳の 2.3%
0%27.1%その他 28.3%

機関

分野

  • Medicine46.9%
  • Biochemistry, Genetics and Molecular Biology26.8%
  • Pharmacology, Toxicology and Pharmaceutics15.8%
  • Computer Science2%
  • Materials Science1.8%
  • Immunology and Microbiology1.1%
  • その他5.6%

トピック

  • Pharmacogenetics and Drug Metabolism7%
  • Colorectal Cancer Treatments and Studies2.8%
  • Drug Transport and Resistance Mechanisms2.7%
  • Computational Drug Discovery Methods2.2%
  • Cancer Genomics and Diagnostics1.8%
  • Cancer Treatment and Pharmacology1.8%
  • その他81.7%

共著者

全論文

検索で開く
  1. Doxorubicin pathways

    著者: Caroline F. Thorn, Connie Oshiro, Sharon Marsh, Tina Hernandez‐Boussard, Howard L. McLeod, Teri E. Klein, Russ B. Altman - Pharmacogenetics and Genomics 2010 被引用: 1,614

  2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

    著者: Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia M. Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab - Clinical Pharmacology & Therapeutics 2017 被引用: 657

  3. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

    著者: Jacob G. Scott, Anders Berglund, Michael J. Schell, I Mihaylov, William J. Fulp, Binglin Yue, Eric A. Welsh, Jimmy J. Caudell, Kamran A. Ahmed, T. Ström, Eric A. Mellon, Puja Venkat, Peter A.S. Johnstone, John A. Foekens, Jae Lee, Eduardo G. Moros, William S. Dalton, Steven A. Eschrich, Howard L. McLeod, Louis B. Harrison, Javier F. Torres–Roca - The Lancet Oncology 2016 被引用: 469

  4. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer

    著者: Dongya Shen, Jia Luo, Ling Chen, Wenjuan Ma, Xiao‐Yuan Mao, Yu Zhang, Juyan Zheng, Yang Wang, Jielin Wan, Shiyu Wang, Jing Ouyang, Hanying Yi, Dongbo Liu, Weihua Huang, Wei Zhang, Zhaoqian Liu, Howard L. McLeod, Yijing He - Cancer Letters 2022 被引用: 111

  5. Pharmacogenomics

    著者: Dan M. Roden, Howard L. McLeod, Mary V. Relling, Marc S. Williams, George A. Mensah, Josh F. Peterson, Sara L. Van Driest - The Lancet 2019 被引用: 405

  6. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

    著者: Nancy Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao, Sean Yoder, Maria E. Balasis, Tania Mesa, David A. Sallman, Jeffrey E. Lancet, Rami S. Komrokji, Alan F. List, Howard L. McLeod, Melissa Alsina, Rachid Baz, Kenneth H. Shain, Dana E. Rollison, Eric Padron - The Lancet Oncology 2016 被引用: 313

  7. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

    著者: Godefridus J. Peters, Harold H.J. Backus, SJ Freemantle, Baukelien van Triest, Giovanni Codacci-Pisanelli, C.L. van der Wilt, Kees Smid, John Lunec, A. Hilary Calvert, Sharon Marsh, Howard L. McLeod, Elisabeth Bloemena, Sybren L. Meijer, Gerrit Jansen, C.J. van Groeningen, Herbert M. Pinedo - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2002 被引用: 430

  8. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

    著者: Shu‐Feng Zhou, Sui Yung Chan, Boon Cher Goh, Eli Chan, Wei Duan, Min Huang, Howard L. McLeod - Clinical Pharmacokinetics 2005 被引用: 510

  9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

    著者: Matthew P. Goetz, Katrin Sangkuhl, Henk‐Jan Guchelaar, Matthias Schwab, Michael A. Province, Michelle Whirl‐Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron HN van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein - Clinical Pharmacology & Therapeutics 2018 被引用: 324

  10. Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

    著者: Dan Rosmarin, Claire Palles, David N. Church, Enric Domingo, Angela Jones, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Anna González‐Neira, Miguel Martín, Daniel J. Sargent, Erin Green, Howard L. McLeod, Ulrich M. Zanger, Matthias Schwab, Michael Braun, Michel Seymour, Lindsay C Thompson, Benjamin Lacas, Valérie Boige, Nuria Ribelles, Shoaib Afzal, Henrik Enghusen, Søren Astrup Jensen, Marie-Christine Etienne-Grimaldi, G. Milano, Mia Wadelius, Bengt Glimelius, Hans Garmo, Milena Gusella, Thierry Lecomte, Pierre Laurent‐Puig, Eva Martinez‐Balibrea, Rohini Sharma, Jesús García‐Foncillas, Zdeněk Kleibl, Alain Morel, Jean‐Pierre Pignon, Rachel Midgley, David Kerr, Ian D. Tomlinson - Journal of Clinical Oncology 2014 被引用: 259

  11. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

    著者: Todd C. Knepper, Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani, Vernon K. Sondak, Jane L. Messina, Michael J. Schell, James A. DeCaprio, Kenneth Y. Tsai, Andrew S. Brohl - Clinical Cancer Research 2019 被引用: 170

  12. When will clinical trials finally reflect diversity?

    著者: Todd C. Knepper, Howard L. McLeod - Nature 2018 被引用: 147

  13. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    著者: William E. Evans, Howard L. McLeod - New England Journal of Medicine 2003 被引用: 1,768

  14. DPYD Testing: Time to Put Patient Safety First

    著者: Sharyn D. Baker, Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El‐Deiry, William E. Evans, William D. Figg, Daniel L. Hertz, J. Kevin Hicks, Suneel Kamath, Pashtoon Murtaza Kasi, Todd C. Knepper, Howard L. McLeod, Peter H. O’Donnell, Mary V. Relling, Michelle A. Rudek, Tristan M. Sissung, D. Max Smith, Alex Sparreboom, Sandra M. Swain, Christine M. Walko - Journal of Clinical Oncology 2023 被引用: 40

  15. PI3K/Akt/mTOR pathway as a target for cancer therapy

    著者: Daniel Morgensztern, Howard L. McLeod - Anti-Cancer Drugs 2005 被引用: 466

  16. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

    著者: Laura B. Ramsey, Samuel G. Johnson, Kelly E. Caudle, Cyrine E. Haidar, Deepak Voora, Russell A. Wilke, Whitney D. Maxwell, Howard L. McLeod, Ronald M. Krauss, D M Roden, QiPing Feng, Rhonda M. Cooper‐DeHoff, Li Gong, Teri E. Klein, Mia Wadelius, Mikko Niemi - Clinical Pharmacology & Therapeutics 2014 被引用: 440

  17. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

    著者: P. Lenzini, J. A. Johnson, Howard L. McLeod, M. J. Rieder, Brian F. Gage, L. Grosso, D. L. Veenstra, C. Eby, R. J. Glynn, D. Voora, T. Langaee, G. Grice, L. E. Farnett, Christina L. Aquilante, S. Marsh, P. M. Ridker, P. E. Milligan, A. E. Rettie, E. Deych, A. Barrett - Clinical Pharmacology & Therapeutics 2008 被引用: 834

  18. Global implementation of genomic medicine: We are not alone

    著者: Teri A. Manolio, Marc Abramowicz, Fahd Al‐Mulla, Warwick P. Anderson, Rudi Balling, Adam C. Berger, Steven B. Bleyl, Aravinda Chakravarti, Wasun Chantratita, Rex L. Chisholm, Vajira H. W. Dissanayake, Michael Dunn, Victor J. Dzau, Bok‐Ghee Han, Tim Hubbard, Anne Kolbe, Bruce R. Korf, Michiaki Kubo, Paul Lasko, Erkki Leego, Surakameth Mahasirimongkol, Partha P. Majumdar, Gert Matthijs, Howard L. McLeod, Andres Metspalu, Pierre Meulien, Satoru Miyano, Yaakov Naparstek, P. Pearl O’Rourke, George P. Patrinos, Heidi L. Rehm, Mary V. Relling, Gad Rennert, Laura Lyman Rodriguez, Dan M. Roden, Alan R. Shuldiner, Sukdeb Sinha, Patrick Tan, Mats Ulfendahl, Robyn L. Ward, Marc S. Williams, John E.L. Wong, Eric D. Green, Geoffrey S. Ginsburg - Science Translational Medicine 2015 被引用: 246

  19. Strategies for enzyme/prodrug cancer therapy.

    著者: Guo Xu, Howard L. McLeod - 2001 被引用: 278

  20. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities

    著者: Jeanette McCarthy, Howard L. McLeod, Geoffrey S. Ginsburg - Science Translational Medicine 2013 被引用: 245

  21. Cytochrome P450 2C9-CYP2C9

    著者: Derek Van Booven, Sharon Marsh, Howard L. McLeod, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Russ B. Altman - Pharmacogenetics and Genomics 2010 被引用: 239

  22. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy

    著者: Susan G. Dorsey, Ian R. Kleckner, Debra L. Barton, Karen M. Mustian, Ann M. O’Mara, Diane St. Germain, Guido Cavaletti, Suzanne C. Danhauer, Dawn L. Hershman, Andrea G. Hohmann, Ahmet Höke, Judith O. Hopkins, Katherine Patterson Kelly, Charles L. Loprinzi, Howard L. McLeod, Supriya G. Mohile, Judith A. Paice, Julia H. Rowland, Daniela Salvemini, Rosalind A. Segal, Elizabeth Smith, Worta McCaskill Stevens, Michelle C. Janelsins - JNCI Journal of the National Cancer Institute 2019 被引用: 126

  23. Genomics and Drug Response

    著者: Liewei Wang, Howard L. McLeod, Richard M. Weinshilboum - New England Journal of Medicine 2011 被引用: 614

  24. Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations

    著者: P. Brent Ferrell, Howard L. McLeod - Pharmacogenomics 2008 被引用: 417